Processa Pharmaceuticals' CEO, David Young, will participate in a panel at the World Orphan Drug Congress, discussing patient-focused drug development and interaction with the FDA. This event may increase the company's visibility and lead to potential partnerships with pharmaceutical and biotech companies, which could positively impact the stock price in the short term.